tetano
Editor, Senior Moderator
Life Sci Alliance
. 2022 Nov 7;6(1):e202201548.
doi: 10.26508/lsa.202201548. Print 2023 Jan.
The potential of a universal influenza virus-like particle vaccine expressing a chimeric cytokine
Kuniaki Nerome[SUP] 1 [/SUP], Toshifumi Imagawa[SUP] 2 3 [/SUP], Shigeo Sugita[SUP] 4 [/SUP], Youta Arasaki[SUP] 2 [/SUP], Kenichi Maegawa[SUP] 2 [/SUP], Kazunori Kawasaki[SUP] 5 [/SUP], Tsuyoshi Tanaka[SUP] 6 [/SUP], Shinji Watanabe[SUP] 7 [/SUP], Hidekazu Nishimura[SUP] 8 [/SUP], Tetsuro Suzuki[SUP] 3 [/SUP], Kazumichi Kuroda[SUP] 9 [/SUP], Isao Kosugi[SUP] 10 [/SUP], Zenta Kajiura[SUP] 11 [/SUP]
Affiliations
Abstract
The efficacy of the current influenza vaccines is frequently reduced because of antigenic drift, a trade-off of developing improved vaccines with broad cross-protective activity against influenza A viruses. In this study, we have successfully constructed a chimeric cytokine (CC) comprising the M2 protein, influenza A neuraminidase stalk, and interleukin-12. We produced virus-like particles (VLPs) containing CC and influenza hemagglutinin (HA) proteins using a baculovirus system in Eri silkworm pupae. The protective efficacy of the CCHA-VLP vaccine was evaluated in mice. The CCFkH5HA-VLP vaccine increased the survival rates of BALB/c mice, infected with a lethal dose of PRH1 and HKH5 viruses, to 80% and 100%, respectively. The results suggested that CCHA-VLP successfully induced potent cross-reactive protective immunity against infection with homologous and heterologous subtypes of the influenza A virus. This is the first study to design a CC-containing HA-VLP vaccine and validate its protective efficacy.
. 2022 Nov 7;6(1):e202201548.
doi: 10.26508/lsa.202201548. Print 2023 Jan.
The potential of a universal influenza virus-like particle vaccine expressing a chimeric cytokine
Kuniaki Nerome[SUP] 1 [/SUP], Toshifumi Imagawa[SUP] 2 3 [/SUP], Shigeo Sugita[SUP] 4 [/SUP], Youta Arasaki[SUP] 2 [/SUP], Kenichi Maegawa[SUP] 2 [/SUP], Kazunori Kawasaki[SUP] 5 [/SUP], Tsuyoshi Tanaka[SUP] 6 [/SUP], Shinji Watanabe[SUP] 7 [/SUP], Hidekazu Nishimura[SUP] 8 [/SUP], Tetsuro Suzuki[SUP] 3 [/SUP], Kazumichi Kuroda[SUP] 9 [/SUP], Isao Kosugi[SUP] 10 [/SUP], Zenta Kajiura[SUP] 11 [/SUP]
Affiliations
- PMID: 36344085
- DOI: 10.26508/lsa.202201548
Abstract
The efficacy of the current influenza vaccines is frequently reduced because of antigenic drift, a trade-off of developing improved vaccines with broad cross-protective activity against influenza A viruses. In this study, we have successfully constructed a chimeric cytokine (CC) comprising the M2 protein, influenza A neuraminidase stalk, and interleukin-12. We produced virus-like particles (VLPs) containing CC and influenza hemagglutinin (HA) proteins using a baculovirus system in Eri silkworm pupae. The protective efficacy of the CCHA-VLP vaccine was evaluated in mice. The CCFkH5HA-VLP vaccine increased the survival rates of BALB/c mice, infected with a lethal dose of PRH1 and HKH5 viruses, to 80% and 100%, respectively. The results suggested that CCHA-VLP successfully induced potent cross-reactive protective immunity against infection with homologous and heterologous subtypes of the influenza A virus. This is the first study to design a CC-containing HA-VLP vaccine and validate its protective efficacy.